



Use of IMAC magnetic beads for simplified detergent screening for optimization of purification workflows of histidine-tagged membrane proteins

Intellectual Property Notice: The Biopharma business of GE Healthcare was acquired by Danaher on 31 March 2020 and now operates under the Cytiva™ brand. Certain collateral materials (such as application notes, scientific posters, and white papers) were created prior to the Danaher acquisition and contain various GE owned trademarks and font designs. In order to maintain the familiarity of those materials for long-serving customers and to preserve the integrity of those scientific documents, those GE owned trademarks and font designs remain in place, it being specifically acknowledged by Danaher and the Cytiva business that GE owns such GE trademarks and font designs.

cytiva.com

GE and the GE Monogram are trademarks of General Electric Company.
Other trademarks listed as being owned by General Electric Company contained in materials that pre-date the Danaher acquisition and relate to products within Cytiva's portfolio are now trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.
Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate.
All other third-party trademarks are the property of their respective owners.
© 2020 Cytiva
All goods and services are sold subject to the terms and conditions of sale of the supplying company operating within the Cytiva business. A copy of those terms and conditions is available on request. Contact your local Cytiva representative for the most current information.
For local office contact information, visit [cytiva.com/contact](https://www.cytiva.com/contact)

CY15125-11Jul20-PT

Use of IMAC magnetic beads for simplified detergent screening for optimization of purification workflows of histidine-tagged membrane proteins

Karin Torstenson, Inger Salomonsson, Erik Mascher, Marianne Carlsson, Pia Liljedahl, and Anna Heijbel
GE Healthcare Bio-Sciences AB, SE-751 84 Uppsala, Sweden

Background

Integral membrane proteins are main targets for development of new pharmaceuticals.

Affinity purification is a powerful tool that has become the prime choice as capture step in membrane protein purification. Recombinant membrane proteins are commonly purified by use of polyhistidine tags and immobilized metal affinity chromatography (IMAC).

The choice of detergent is the major key factor for successful solubilisation and further purifications of integral membrane proteins to avoid protein loss and inactivation. Therefore a detergent screen is often necessary to find the optimal detergent for each purpose.

The use of the Membrane Protein Purification Kit allows for rapid, small-scale screening of optimal purification conditions for histidine-tagged membrane proteins. The kit contains IMAC magnetic beads pre-charged with Ni²⁺-ions (His Mag Sepharose™ Ni), selected detergents, buffers and an easy-to-follow protocol.

Screening for optimal detergent(s) for purification conditions of some integral membrane proteins was performed using the Membrane Protein Purification Kit.

The detergents screen workflow is outlined in Figure 1.




Fig 1. Detergent screening workflow.

Screen for optimal detergent(s) for solubilization/purification of (His)₉-cytochrome *bo*₃ ubiquinol oxidase

Seven detergents (see Table 1) were used for screening of optimal detergent(s) for (His)₉-cytochrome *bo*₃ ubiquinol oxidase (expressed in *E. coli*). Analyses were done by Western blot (Fig 2A) using enhanced chemoluminescence for quantitative evaluations (Fig 2B) and gel filtration (Fig 2C) was used to determine size homogeneity and purity of the membrane protein.

This detergent screen (Fig 2A and 2B) shows that DDM, DM or LDAO are suitable for solubilization and purification of histidine tagged cytochrome *bo*₃ ubiquinol oxidase.

FOS12 might also be considered since this detergent seems to give a slightly purer and a more homogeneous preparation (Fig 2C).

Table 1. Concentrations of the respective detergents for solubilization and purification

Detergents	Solubilization	Purification
n-Dodecyl-β-D-maltoside (DDM)	1%	0.1%
n-Decyl-β-D-maltoside (DM)	1%	0.2%
Lauryldimethylamine-N-oxide (LDAO)	1%	0.2%
n-Dodecylphosphocholine (FOS12)	1%	0.1%
Dodecyl octaethyleneglycol ether (C ₁₂ E ₈)	1%	0.1%
Cyclohexyl-1-pentyl-β-D-maltoside (CYMAL-5)	1%	0.2%
n-Octyl-β-D-glucoside (OG)	2%	1.0%




Fig 2. Analyses of purified cytochrome *bo*₃ ubiquinol oxidase.

Scale up preparation of YedZGFP-(His)₈

A detergent screen for YedZGFP-(His)₈ (expressed in *E. coli*) had identified DM as a suitable candidate for solubilization/purification of YedZGFP-His (data not shown).

A scale up preparation in the presence of 0.2% DM, using a 1-mL HisTrap™ HP column, was done of material solubilized in 1% DM.

The main component in the purified fraction (Fig 3A) was the YedZGFP-His target protein. The SDS-PAGE profile (Fig 3B) suggests that a second purification step is required to obtain highly pure YedZGFP-His.




Fig 3. Preparation of YedZGFP-His on 1-mL HisTrap HP in 0.2% DM. A) Chromatographic profile; (blue curve A₂₈₀ and green curve A₄₉₀) B) Deep Purple™-stained SDS-PAGE image.

GE, imagination at work, and GE monogram are trademarks of General Electric Company. Deep Purple, ECL, HisTrap, Sepharose, and Superdex are trademarks of GE Healthcare companies. Deep Purple Total Protein Stain is exclusively licensed to GE Healthcare from Fluorotechnics Pty Ltd. Deep Purple Total Protein Stain may only be used for applications in life science research. Deep Purple is covered under a granted patent in New Zealand entitled "Fluorescent Compounds", patent number 522291 and equivalent patents and patent applications in other countries. ECL Plus contains Lumigen PS3 substrate and is sold under exclusive license from Lumigen Inc. IMAC Sepharose products and Ni Sepharose products (Histidine-tagged protein purification, Lab products). Purification and preparation of fusion proteins and affinity peptides comprising at least two adjacent histidine residues may require a license under US patent numbers 5,284,933 and 5,310,663, and equivalent patents and patent applications in other countries (assignee: Hoffman La Roche, Inc.).

All third party trademarks are the property of their respective owners. © 2010–2011 General Electric Company – All rights reserved. First published Dec. 2010. All goods and services are sold subjects to the terms and conditions of sale of the company within GE Healthcare which supplies them. A copy of these terms and conditions is available on request. Contact your local GE Healthcare representative for the most current information. GE Healthcare Bio-sciences AB, Björkgatan 30, 751 84 Uppsala, Sweden.